Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Do analysts rate BMY or AMGN?

Bristol Myers Squibb presently has a consensus price target of $56.38, indicating a potential upside of 16.85%. Amgen has a consensus price target of $303.76, indicating a potential upside of 2.47%. Given Bristol Myers Squibb's higher probable upside, equities research analysts plainly believe Bristol Myers Squibb is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Amgen	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.33

Is BMY or AMGN a better dividend stock?

Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.1%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays out 100.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Amgen has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do institutionals and insiders believe in BMY or AMGN?

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media refer more to BMY or AMGN?

In the previous week, Bristol Myers Squibb had 11 more articles in the media than Amgen. MarketBeat recorded 70 mentions for Bristol Myers Squibb and 59 mentions for Amgen. Amgen's average media sentiment score of 1.22 beat Bristol Myers Squibb's score of 1.08 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	37 Very Positive mention(s)	10 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive
Amgen	45 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more risk and volatility, BMY or AMGN?

Bristol Myers Squibb has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Which has higher valuation and earnings, BMY or AMGN?

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.30B	2.03	-$8.95B	$2.48	19.45
Amgen	$33.42B	4.77	$4.09B	$12.23	24.24

Is BMY or AMGN more profitable?

Amgen has a net margin of 18.96% compared to Bristol Myers Squibb's net margin of 10.58%. Amgen's return on equity of 174.71% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	10.58%	80.04%	14.69%
Amgen	18.96%	174.71%	13.12%

Summary

Amgen beats Bristol Myers Squibb on 13 of the 19 factors compared between the two stocks.